EyePoint, Inc. Common Stock

EYPT XNAS • LABORATORY ANALYTICAL INSTRUMENTS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

1.1B

Short interest (May 15)

16.9%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.39%

↓ 10.8%

Available Shares

600K

↓ 43.2%

Price Chart

Company Overview

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Company Info

Exchange: NASDAQ

Industry: LABORATORY ANALYTICAL INSTRUMENTS

CIK: 0001314102

Asset Type: CS

Market Data

Market Cap: $1,050,531,463

Employees: 214

Status: Active

Short Interest

Current Borrow Fee 0.39%

Range: 0.36% - 0.39%

Available Shares 600K

Range: 450K - 600K

Recent Changes

Fee Change: ↑ 1.7%

Available Change: ↓ 11.1%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime